Alteplase(Actilyse) commonly known as tissue plasminogen activator (tPA), is a medication used primarily in the treatment of acute ischemic stroke and pulmonary embolism. It belongs to a class of drugs called thrombolytics, which work by dissolving blood clots that are blocking blood flow to vital organs.
In ischemic stroke, Alteplase is administered intravenously to break down the clot causing the stroke, potentially restoring blood flow to the affected area of the brain and reducing neurological damage. When used promptly after the onset of stroke symptoms, Alteplase can significantly improve outcomes and reduce disability.
Similarly, in pulmonary embolism, Alteplase is given intravenously to dissolve blood clots in the lungs, relieving symptoms and preventing further complications.
However, Alteplase carries certain risks, including bleeding, which can sometimes be severe, especially if administered inappropriately or in patients with certain medical conditions. Therefore, its use requires careful consideration of the potential benefits weighed against the risks.
Alteplase is typically administered under the guidance of healthcare professionals in hospital settings, where patients can be closely monitored for any adverse reactions. It is crucial to adhere to strict protocols for its administration and to promptly recognize and manage any complications that may arise.
